Meus Peptídeos
NeuroprotetorFPF 1070

Cerebrolysin

Mixture of low molecular weight peptides and amino acids derived from purified porcine brain. Approved in more than 40 countries for stroke, dementia, and traumatic brain injury. Not approved in the US. One of the most clinically studied neurotrophics, with over 200 clinical studies.

Last updated:: 13/04/2026

Research Status

Pré-clínicoFase 1Fase 2Fase 3Aprovado

ANVISA (Brazil)

Not regulated

FDA (USA)

Not regulated

EMA (Europe)

Approved

Mechanism of Action

Cerebrolysin contains peptide fragments that mimic the action of natural neurotrophic factors (BDNF, GDNF, NGF, CNTF). It promotes neuroplasticity, neuroprotection, neurogenesis, and synaptogenesis. It acts on multiple pathways simultaneously, unlike single molecules that target only one.

Study Protocols

Dosages and regimens used in published clinical studies. This does not constitute a medical prescription.

Recuperação pós-AVC / doença de Alzheimer

Intravenosa (IV) ou Intramuscular (IM)
1
AVC agudo30 mL (diluído em salina)1x/dia IV · 10–21 dias
2
Alzheimer10–30 mL1x/dia IV · 4 semanas, ciclos com intervalo de 2 meses

Mistura de peptídeos neutróficos derivados de cérebro suíno. Aprovado em >45 países (não nos EUA). Ensaio CASTA demonstrou benefício funcional pós-AVC.

Benefits

Stroke recovery

Proven

Meta-analyses of clinical trials demonstrate improved functional recovery post-stroke when administered within the first 72 hours. Approved for this indication in 40+ countries.

View study

Dementia and Alzheimer's

Under research

Clinical studies show modest improvement in cognitive function in patients with mild to moderate Alzheimer's. Mixed results in meta-analyses.

Traumatic brain injury

Under research

Clinical studies in TBI show neuroprotective potential, but evidence is still insufficient for a definitive recommendation.

Risks and Side Effects

Allergic reaction

Moderate(Rare)

Being derived from porcine brain, it may cause allergic reactions in sensitive individuals.

Dizziness and agitation

Low(Uncommon)

Mild neurological side effects reported in clinical studies.

Internet vs. Science

What people say online compared to the actual scientific evidence.

Super brain drug

Partially true

What they claim

Cerebrolysin regenerates neurons and cures brain damage.

Actual evidence

It has over 200 clinical studies and approval in 40+ countries — far more evidence than most peptides. Real efficacy in stroke recovery. But it does not 'regenerate' lost neurons and results in Alzheimer's are modest. Not FDA-approved due to issues with standardization of the biological product.

Studies and References (1)

Cerebrolysin in Acute Ischemic Stroke: A Systematic Review

Bornstein NM, Guekht A, Vester J, et al.Stroke (2018)

Meta-analysis

Meta-análise de 6 RCTs demonstrou que Cerebrolysin melhora significativamente a recuperação funcional global em pacientes com AVC isquêmico agudo.

PubMed

Frequently Asked Questions

Why isn't Cerebrolysin approved in the US?

The FDA requires rigorous standardization of composition for approval. Since Cerebrolysin is a complex mixture of peptides derived from porcine brain, each batch may have slightly different composition, making it difficult to meet FDA criteria. It is approved in over 40 countries including Germany, Russia, China, and South Korea.

Important notice

This content is strictly informational and educational, based on published scientific research. It does not constitute medical advice, prescription, or encouragement to use any substance. Always consult a qualified physician before starting any treatment.

How to Obtain

This is an approved medication. A medical prescription is required for purchase.